Sivextro, to treat MRSA skin infections, receives recommendation from FDA Anti-Infective Drugs Advisory Committee
PRESS RELEASE Cubist Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational More...
FDA accepts Cubist’s NDA for the investigational antibiotic tedizolid to treat MRSA infections
PRESS RELEASE Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for its investigational antibiotic tedizolid More...